Melanoma — Trials · CancerIndex

Clinical trials

Registered studies

3,221 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 605
Recruiting: 316
Ph III recruiting: 30
Growth YoY: +37.2%
Industry share: 33%
Top sponsor: M.D. Anderson Cancer Center
Termination share: 37.5%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (571)

clinicaltrialsPublishedShowing 101–114 of 114 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT01689870	Study of the Combination of Anti-OX40 and Ipilimumab in Patients With Metastatic Melanoma	withdrawn	Phase 1 / Phase 2	0	Ludwig Institute for Cancer ResearchOTHER	0	Apr 1, 2014	clinicaltrials
NCT01933061	Study to Determine Efficacy and Safety of CC-486 With Nab-Paclitaxel Versus Nab-Paclitaxel in Patients With Chemotherapy naïve Metastatic Melanoma	withdrawn	Phase 2	0	Celgene CorporationINDUSTRY	0	Feb 4, 2014	clinicaltrials